Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 79 publications
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.
Journal: Nature communications
Published: August 01, 2025
A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.
Journal: Nature cancer
Published: March 17, 2025
A phase I clinical trial of lenalidomide combined with bortezomib for acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantation.
Journal: Leukemia research
Published: November 07, 2024
CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.
Journal: Best practice & research. Clinical haematology
Published: October 07, 2024
Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.
Journal: Best practice & research. Clinical haematology
Published: September 30, 2024
Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 24, 2024
Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire.
Journal: Nature communications
Published: July 18, 2024
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.
Journal: Cancer immunology research
Published: June 05, 2024
A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.
Journal: bioRxiv : the preprint server for biology
Published: May 27, 2024
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.
Journal: Blood cancer journal
Published: February 05, 2024
Last Updated: 09/26/2026